Frank Yocca - Aug 1, 2025 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Role: Chief Scientific Officer
Signature: /s/ Richard Steinhart, Attorney-in-Fact for Frank Yocca, Ph.D
Stock symbol: BTAI
Transactions as of: Aug 1, 2025
Transactions value $: $0
Form type: 4
Date filed: 8/5/2025, 08:00 PM
Previous filing: Jul 22, 2025
Next filing: Sep 16, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Yocca Frank	Chief Scientific Officer	C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, 12TH FLOOR, NEW HAVEN	/s/ Richard Steinhart, Attorney-in-Fact for Frank Yocca, Ph.D	2025-08-05	0001733272

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BTAI	Restricted Stock Units	Award	$0	+9K		$0.00	9K	Aug 1, 2025	Common Stock	9K		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2	On August 1, 2025 (the "Grant Date"), the Reporting Person was granted 9,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date.